To investigate the prevalence of neutralizing antibodies against adeno-associated virus in hemophiliacs and healthy adults
Not Applicable
- Conditions
- hemophiliacs and healthy adults
- Registration Number
- JPRN-UMIN000039069
- Lead Sponsor
- Jichi Medical University
- Brief Summary
The Seroprevalence of anti-AAV neutralizing antibody for various AAV serotypes was 22.2% for AAV1, 24.5% for AAV2, 29.2% for AAV3B, 22.7% for AAV5, 23.1% for AAV6, 24.1% for AAV7, 20.4% for AAV8, 21.3% for AAV9 and 23.6% for AAVrh10. There was no clear difference in the positivity rates between healthy subjects and hemophiliacs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 227
Inclusion Criteria
Not provided
Exclusion Criteria
1) The person who cannot obtain informed consent 2) Those who are treated with antibody drugs 3) Those who are treated by systemic administration of immunosuppressants (oral and injection) 4) Patients with the possibility of immunological abnormalities such as severe inflammatory diseases 5)The person judged to be ineligible by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method